Adagene Inc. (ADAG) Appoints Cuong Do to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
November 21, 2022 4:05 PM ESTSAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (Adagene) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagenes board of directors (the Board) as an independent director. He will also serve as an audit committee member.
Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimers Disease, Parkinsons disease and refractory Ascites. Prior to BioVie, Mr. Do was President of Samsungs Global Strategy Group where he... More



